OptiBiotix Health Enhances SweetBiotix Production with New Enzymatic Process

OptiBiotix Health ( (GB:OPTI) ) has provided an update.

OptiBiotix Health has announced significant advancements in the production of its SweetBiotix® product line, which consists of natural, high-fiber, low-calorie sweeteners designed to replace sugar and artificial substitutes. The company has developed a new enzymatic process that increases yield and purity, reduces production costs, and enhances the taste profile of SweetBiotix products. This innovation not only strengthens OptiBiotix’s market position by addressing health concerns associated with sugar substitutes but also opens up new partnership opportunities with sugar producers. The breakthrough is expected to boost investor confidence and expand the commercial potential of SweetBiotix products.

More about OptiBiotix Health

OptiBiotix Health plc is a life sciences company focused on developing products that modulate the human microbiome to prevent and manage diseases. The company offers a diverse range of microbiome-based ingredients and products, including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix®, and Microbiome Modulators. OptiBiotix also has interests in skincare through SkinBioTherapeutics PLC and probiotics through ProBiotix Health plc, catering to the growing consumer interest in healthcare solutions worldwide.

Average Trading Volume: 245,586

Technical Sentiment Signal: Sell

Current Market Cap: £8.16M

Learn more about OPTI stock on TipRanks’ Stock Analysis page.